Easy read childhood nasal flu leaflet

Public Health England, September 2016

This leaflet is aimed at children with learning difficulties who are offered the nasal flu vaccination. It provides easy to read advice on:

  • the flu virus and why you need the vaccine
  • signs and symptoms of flu
  • how the nasal flu spray is given

Click here to access the leaflet.

Advertisements

UK immunisation schedule: the green book, chapter 11

Public Health England, September 2016

This chapter has been fully updated to reflect all the recent changes to the routine childhood immunisation schedule, as well as those to the adult programme.

The overall aim of the UK’s routine immunisation schedule is to provide protection against the following vaccine-preventable infections:

diphtheria
tetanus
pertussis (whooping cough)
haemophilus influenzae type b (Hib)
polio
meningococcal disease (certain serogroups)
measles
mumps
rubella
pneumococcal (certain serotypes)
human papillomavirus types (certain serotypes)
rotavirus
influenza
shingles

Click here to access this resource online.

Influenza vaccination for healthcare workers in the UK: appraisal of systematic reviews and policy options

BMJ Open, 13 September 2016

The UK Department of Health recommends annual influenza vaccination for healthcare workers, but uptake remains low. For staff, there is uncertainty about the rationale for vaccination and evidence underpinning the recommendation.

This systematic appraisal of systematic reviews aims to clarify the rationale, and evidence base, for influenza vaccination of healthcare workers from the occupational health, employer and patient safety perspectives.

Click here to access the full text.

NHS England to recommission flu vaccinations in community pharmacies for 2016/17

NHS England, May 2016

NHS England has announced it will recommission the Community Pharmacy Seasonal Influenza Vaccination programme in 2016/17, after nearly a quarter of a million more people benefited from vaccinations in a community pharmacy setting during the previous year.

Click here to read more.

Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis

BMJ, 12 May 2015

This paper aims to assess the reduction in the vaccine preventable burden of cancer in men if boys are vaccinated along with girls against oncogenic human papillomavirus (HPV) using a Bayesian evidence synthesis approach to evaluate the impact of vaccination against HPV types 16 and 18 on the burden of anal, penile, and oropharyngeal carcinomas among heterosexual men and men who have sex with men.

Click here to access the full text.

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

BMJ, 7 January 2015

This study investigates the incremental cost effectiveness of two dose human papillomavirus vaccination and of additionally giving a third dose.

The results show that giving at least two doses of vaccine seems to be highly cost effective across the entire range of scenarios considered at the quadrivalent vaccine list price of £86.50 (€109.23; $136.00) per dose. If two doses give only 10 years’ protection but adding a third dose extends this to lifetime protection, then the third dose also seems to be cost effective at £86.50 per dose (median incremental cost effectiveness ratio £17 000, interquartile range £11 700-£25 800). If two doses protect for more than 20 years, then the third dose will have to be priced substantially lower (median threshold price £31, interquartile range £28-£35) to be cost effective. Results are similar for a bivalent vaccine priced at £80.50 per dose and when the same scenarios are explored by parameterising a Canadian model (HPV-ADVISE) with economic data from the United Kingdom.

The study concludes that two dose human papillomavirus vaccine schedules are likely to be the most cost effective option provided protection lasts for at least 20 years. As the precise duration of two dose schedules may not be known for decades, cohorts given two doses should be closely monitored.

Click here to access the full text article.  You will need to login with your Athens password to view this article.

All Lancashire Care staff are eligble to register for an Athens password.  Please click here to register for an Athens password.